Therapure Biopharma Inc. has received a $20 million contribution under the Federal Economic Development Agency for Southern Ontario’s Advanced Manufacturing Fund (AMF). Minister Gary Goodyear and MP Brad Butt announced the news at Therapure’s Meadowpine manufacturing facility in Mississauga.

The Fund was created to support the development of transformative technologies by Ontario manufacturers and allow them to compete with the rest of the world. Therapure is a manufacturer of biologics for medical use with particular expertise in plasma-derived proteins. Leveraging this expertise, Therapure has developed a proprietary technology called PlasmaCap Expanded Bed Adsorption (PlasmaCap EBA), which yields more protein from the same amount of plasma, and separates the proteins faster, and at lower cost than existing processes used worldwide. The support from the AMF will allow Therapure to advance a new technology for manufacturing plasma proteins. As a result of this research, development and manufacturing opportunity, approximately 91 new jobs will be created at its Mississauga facility.

“This investment, for which we thank the Government of Canada, will help us expand our scope and accelerate our growth in the plasma proteins industry,” said Nick Green, president and chief executive officer, Therapure. “This expansion was a natural progression for Therapure after having established ourselves as a successful contract manufacturer of complicated biologics with additional expertise in plasma-derived proteins. We believe that our PlasmaCap EBA technology delivers the highest yields in the industry and will allow us to produce safe, quality, life-changing products for patients.”